John H. Abeles
Director/Board Member at MEDITE CANCER DIAGNOSTICS INC
Profile
John H.
Abeles is the founder of MedVest, Inc. (founded in 1980) and ContraFect Corp.
(founded in 2008).
He is also the founder of Bryologyx, Inc., Oncolyze, Inc...
Dr. Abeles's current job(s) include Chairman at UniMedica, Inc. (since 1998), Director at Alison Raffaele Cosmetics, Inc., Director at CombiMatrix Molecular Diagnostics, Inc. (since 1996), Director at Baystar Biosciences, Director at Medezrin Ltd., Director at Medisync Midwest LLC, Director at Higuchi Bioscience Center (since 1997), Director at International Opera Alliance, Director at OHK Medical Devices, Inc., Independent Director at MEDITE Cancer Diagnostics, Inc. (since 1999), Director at Pattern Pharma, Inc., Assistant Professor-Clinical Pharmacology at International University of Health Sciences (since 1998), Member at Players Club, and Managing Member at Dalyda Finance LLC.
Dr. Abeles's former job(s) include Director at I-Flow Corp.
(1985-2009), Director at Oryx Technology Corp., Director at DUSA Pharmaceuticals, Inc., Director at CytoCore, Inc. (1999-2011), Independent Director at CombiMatrix Corp.
(2012), Director at Neurotrope, Inc. (2014-2015), Director at The New Group, Inc., Director at GliaMed, Inc., Director at Etubics Corp., Director at ReAble Therapeutics, Inc., Managing Director at Hadean Ventures AS (2017), General Partner at Northlea Partners LLLP, Advisor at Roberts Mitani LLC, and Analyst at Kidder Peabody (1980).
Dr. Abeles's education history includes undergraduate and doctorate degrees from the University of Birmingham.
Dr. Abeles is also the founder of Bryologyx, Inc., Oncolyze, Inc...
John H. Abeles active positions
| Companies | Position | Start |
|---|---|---|
| MEDITE CANCER DIAGNOSTICS INC | Director/Board Member | 1999-04-30 |
| Combimatrix Molecular Diagnostics, Inc. | Director/Board Member | 1995-12-31 |
Oncolyze, Inc.
 Oncolyze, Inc. BiotechnologyHealth Technology Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation. | Founder | - |
Bryologyx, Inc.
 Bryologyx, Inc. Pharmaceuticals: MajorHealth Technology Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA. | Founder | - |
| Higuchi Bioscience Center | Director/Board Member | 1996-12-31 |
| Dalyda Finance LLC | Corporate Officer/Principal | - |
OHK Medical Devices, Inc.
 OHK Medical Devices, Inc. Medical SpecialtiesHealth Technology OHK Medical Devices, Inc. develops and manufactures self-contained, sterile, exsanguinating tourniquet products. Its products include hand and wrist, foot and ankle, upper extremity, lower extremity and pediatrics. The company was founded by Noam Gavriely in 1999 and is headquartered in Grandville, MI. | Director/Board Member | 2011-10-06 |
| Players Club | Corporate Officer/Principal | 2010-07-13 |
International Opera Alliance
 International Opera Alliance Miscellaneous Commercial ServicesCommercial Services International Opera Alliance is an entertainment company focused on musical and arts activities. The company is headquartered in Fairfax, VA. | Director/Board Member | 2010-07-13 |
| ░░░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Former positions of John H. Abeles
| Companies | Position | End |
|---|---|---|
| ░░░░░░ ░░░░░░░░ ░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Training of John H. Abeles
| University of Birmingham | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ORYX TECHNOLOGY CORP. | Producer Manufacturing |
| CONTRAFECT CORPORATION | Health Technology |
| MEDITE CANCER DIAGNOSTICS INC | Health Technology |
| Private companies | 28 |
|---|---|
I-Flow Corp.
 I-Flow Corp. Medical SpecialtiesHealth Technology I-Flow Corp. designs, develops and manufactures ambulatory drug delivery systems. Its products include portable infusion pumps, catheters and pain kits. The company was founded in 1985 and is headquartered in Lake Forest, CA. | Health Technology |
DUSA Pharmaceuticals, Inc.
 DUSA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company, which develops and markets Levulan Photodynamic Therapy technology platform for the prevention and treatment of dermatological skin conditions. Its products include levulan kerastick, BLU-U and clindareach. The company was founded by D. Geoffrey Shulman on February 21, 1991 and is headquartered in Wilmington, MA. | Health Technology |
| Northlea Partners LLLP | |
CytoCore, Inc.
 CytoCore, Inc. Medical SpecialtiesHealth Technology CytoCore, Inc. develops, manufactures and sells an integrated family of products for the detection, diagnosis and treatment of cancer. The company markets its products under the trade name CytoCore Solutions, which is intended to address sample collection, specimen preparation, specimen evaluation, including detection/screening and diagnosis, treatment and patient monitoring within vertical markets related to specific cancers. The company also designs, markets and sells a companion product to detect breast cancer. It intends to focus on the expansion of its products for the treatment of gynecological cancer as well as bladder, lung, and breast cancers amongst others. CytoCore was founded in December 1998 and is headquartered in Chicago, IL. | Health Technology |
CombiMatrix Corp.
 CombiMatrix Corp. BiotechnologyHealth Technology CombiMatrix Corp. engages in the provision of clinical diagnostic services. It offers cytogenomic testing for preimplantation genetic testing, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. The company was founded in October 1995 and is headquartered in Irvine, CA. | Health Technology |
Roberts Mitani LLC
 Roberts Mitani LLC Investment Banks/BrokersFinance Founded in 1992, Roberts Mitani LLC is an independent broker/dealer headquartered in New York City. The firm provides a full array of trading and execution services for their clients. They do not provide any internal research | Finance |
Alison Raffaele Cosmetics, Inc.
 Alison Raffaele Cosmetics, Inc. Specialty StoresRetail Trade Alison Raffaele Cosmetics, Inc. manufactures cosmetics and facial makeup products. Its products include powder, lipstick, lip gloss and blush, tools, and brushes. The firm was founded by Alison Raffaele Tatem in 2000 and is headquartered in Cliffside Park, NJ. | Retail Trade |
Neurotrope, Inc.
 Neurotrope, Inc. Pharmaceuticals: MajorHealth Technology Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY. | Health Technology |
The New Group, Inc.
 The New Group, Inc. Advertising/Marketing ServicesCommercial Services The New Group, Inc. provided digital marketing and advertising services. It focused on brand-reinforcing social media campaigns, mobile applications, micro-sites, and viral marketing. The company was founded by Doug New in 1993 and was headquartered in Portland, OR. | Commercial Services |
| Kidder Peabody | Finance |
| MedVest, Inc. | |
GliaMed, Inc.
 GliaMed, Inc. Pharmaceuticals: MajorHealth Technology GliaMed, Inc. develops therapeutic products. Its products are used for the treatment of brain tumors and neurodegenerative diseases. The company develops topical therapies that accelerate wound healing by promoting regeneration of nerves and structures in the skin that are damaged from trauma. GliaMed was founded by David E. Weinstein in September, 2001 and is headquartered in New York, NY | Health Technology |
| Combimatrix Molecular Diagnostics, Inc. | |
| UniMedica, Inc. | |
Etubics Corp.
 Etubics Corp. BiotechnologyHealth Technology Etubics Corp. develops commercial prophylactic vaccines and immunotherapy products. It offers proprietary immunization platform technology called the etubics platform that develops therapeutic vaccines for colon and breast cancers and preventative vaccines for H1N1 Influenza and HIV. The company was founded by Frank R. Jones in 2003 and is headquartered in Seattle, WA. | Health Technology |
| Baystar Biosciences | |
| Medezrin Ltd. | |
Medisync Midwest LLC
 Medisync Midwest LLC Miscellaneous Commercial ServicesCommercial Services Medisync Midwest LLC provides consultation services. It offers practice management partnership, clinical research, volume to value planning, diagnostic assessments, and HCC program. The company is headquartered in Cincinnati, OH. | Commercial Services |
| ReAble Therapeutics, Inc. | Health Technology |
| Higuchi Bioscience Center | |
International Opera Alliance
International Opera Alliance Miscellaneous Commercial ServicesCommercial Services International Opera Alliance is an entertainment company focused on musical and arts activities. The company is headquartered in Fairfax, VA. | Commercial Services |
| Players Club | |
OHK Medical Devices, Inc.
OHK Medical Devices, Inc. Medical SpecialtiesHealth Technology OHK Medical Devices, Inc. develops and manufactures self-contained, sterile, exsanguinating tourniquet products. Its products include hand and wrist, foot and ankle, upper extremity, lower extremity and pediatrics. The company was founded by Noam Gavriely in 1999 and is headquartered in Grandville, MI. | Health Technology |
| Dalyda Finance LLC | |
Hadean Ventures AS
 Hadean Ventures AS Investment ManagersFinance Hadean Ventures AS (Hadean Ventures) is a venture capital firm that manages alternative investment funds. The firm was founded by Ingrid Helene Teigland Akay in 2014 and is headquartered in Oslo, Norway. | Finance |
Pattern Pharma, Inc.
 Pattern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pattern Pharma, Inc. engages in the pharmaceutical industry. Its product named P2PAR addresses the immune failure which underlies infectious diseases and cancers. The company is headquartered in Toronto, Canada. | Health Technology |
Bryologyx, Inc.
Bryologyx, Inc. Pharmaceuticals: MajorHealth Technology Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA. | Health Technology |
Oncolyze, Inc.
Oncolyze, Inc. BiotechnologyHealth Technology Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- John H. Abeles
